Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization

Uemoto, Riyo; Nakasato-Sonn, Houmei; Kawagoe, Tatsukata; Meguro, Akira; Okada, Eiichi; Mizuki, Nobuhisa

doi:10.1007/s00417-011-1921-4

Cited by 16 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This confirms previous reports that chorioretinal atrophy can develop long after CNV has regressed not only in nontreated eyes, but also in eyes treated with PDT and/or anti-VEGF [7,27,28]. Therefore, more studies with long-term follow-up are needed to determine the real effectiveness of different treatments for myopic CNV.…”

Section: Discussionsupporting

confidence: 87%

Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization

et al. 2014

View full text Add to dashboard Cite

Purpose: To evaluate the long-term progression of myopic maculopathy and functional outcome after treatment of myopic choroidal neovascularization (CNV) with photodynamic therapy (PDT) and/or intravitreal ranibizumab (IVR). Methods: Retrospective study with a cross-sectional evaluation. Eyes were assigned to 4 groups (PDT, IVR, PDT + IVR, dry myopic maculopathy) and evaluated with best-corrected visual acuity, color fundus photography and spectral-domain optical coherence tomography. Chorioretinal atrophy progression was quantified. Results: Fifty-four eyes were included with a mean follow-up of 80.6 ± 28.0 months. The prevalence of diffuse, patchy and macular atrophy increased during the follow-up, in contrast with tessellated fundus, lacquer cracks and active CNV. Progression of macular atrophy was significant in the 3 treatment groups (p < 0.05) and predictive of visual acuity. It depended on age, degree of myopia and presence of staphyloma, but not on the type of treatment. Conclusions: The long-term functional outcome of eyes with myopic CNV is more dependent on the progression of macular atrophy, and not on the type of treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recently, several authors reported that the initial CNV size, the number of intravitreal injections and the duration of the follow-up periods were the factors most significantly associated with an enlargement of the choroidal atrophy around a regressed myopic CNV [29,30]. There still is much debate about the influence of multiple repeated intravitreal injections of bevacizumab on the development and enlargement of choroidal atrophy in patients affected by myopic CNV [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

“…There still is much debate about the influence of multiple repeated intravitreal injections of bevacizumab on the development and enlargement of choroidal atrophy in patients affected by myopic CNV [28][29][30]. Uemoto et al showed that eyes with an enlargement of the CRA area had received significantly more intravitreal injections of bevacizumab than eyes whose choroidal thickness was unchanged [30]. The authors suggested that this finding may be ascribed to an increase in the tension on the RPE given by the high number of intravitreal injections of VEGF inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes

Sarao

Veritti

Macor

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The relationship between the development of CRA and the number of anti-VEGF injections is unclear,; in a study by Ahn et al subfoveal choroidal thickness was found to be significantly decreased following anti-VEGF therapy which may play a role in eventual development of CRA [89]. Two studies provide conflicting evidence on the effects of anti-VEGF treatments on CRA size and enlargement [87,90]. Recently with the advent of swept source OCT, what was previously reported as CRA post mCNV is now postulated to be a macular BM defect instead.…”

Section: • Unclear Benefit Of Combination Of Anti-vegf Withmentioning

confidence: 99%

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Teo

Lee

Cheung

2016

Drugs

View full text Add to dashboard Cite

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.

show abstract

Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization

Abstract: Our findings showed that eyes with a larger CNV at the baseline and longer follow-up period had a greater risk of developing a ChRA like non-treatment, even if IVB treatment was performed for mCNV.

Cited by 16 publications

References 13 publications

Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization

Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization

Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Contact Info

Product

Resources

About